In our cross-sectional retrospective study, we aimed to provide an in-depth analysis of EBV IgG and IgM antibodies against different EBV lifecycle proteins, and of treatment effects on EBV antibody titers to obtain a complete picture regarding possible EBV reactivation and the specific EBV immune response in MS patients. The gene discussed is CD40LG; the disease is myeloid sarcoma.